Fang Ni
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Fang Ni
Fang Ni was last confirmed as Board Member at Black Diamond Therapeutics, Inc. (BDTX) in a filing dated April 24, 2024. Earlier roles on record: CFO at Black Diamond Therapeutics, Inc. (BDTX) until October 7, 2024. Black Diamond Therapeutics, Inc. reported in an 8-K filed October 7, 2024 that Fang Ni was terminated as Chief Business Officer, Chief Financial Officer and principal financial officer, effective October 7, 2024. The proxy statement of Black Diamond Therapeutics, Inc. reports total compensation of $1,489,526 for Fang Ni in fiscal 2023, including a base salary of $450,865. Disclosed compensation is on record for 3 fiscal years.
“On October 7, 2024, Black Diamond Therapeutics, Inc. (the "Company") terminated Fang Ni, Pharm. D. without Cause (as such term is defined in his employment agreement with the Company, which was filed as Exhibit 10.12 to the Company's Annual Report on Form 10-K filed on March 9, 2023 (the "Employment Agreement") as Chief Business Officer, Chief Financial Officer and principal financial officer of the Company, in each case, effective as of October 7, 2024 (the "Separation"), in connection with a corporate restructuring plan (as described in further detail below).”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
2021-11-19–2024-10-07
-
2021-01-01–2024-04-24
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Black Diamond Therapeutics, Inc. (BDTX) | Pharm.D. Chief Business Officer and Interim Chief Financial Officer | $450,865 | $1,489,526 |
| 2022 | Black Diamond Therapeutics, Inc. (BDTX) | Pharm.D. Chief Business Officer and Interim Chief Financial Officer | $411,740 | $909,759 |
| 2021 | Black Diamond Therapeutics, Inc. (BDTX) | Pharm.D. Chief Business Officer and Chief Financial Officer | $388,101 | $1,674,570 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.